Last quarter (Q3 2023), Cyclo Therapeutics's total revenue was $495.50K, an increase of Infinity% from the same quarter last year. In Q3, Cyclo Therapeutics's net income was $-4.77M. See Cyclo Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 951.83K	$ 1.38M	$ -122.83K	$ 903.38K	$ 1.01M	$ 1.01M
Cost of Revenue	$ -38.17K	$ -24.08K	$ 185.12K	$ 66.40K	$ 75.49K	$ 105.03K
Gross Profit	$ 650.76K	$ 1.40M	$ -185.12K	$ 836.98K	$ 931.71K	$ 906.45K
Operating Expense	$ 9.63M	$ 16.83M	$ 15.57M	$ 9.80M	$ 8.32M	$ 5.16M
Operating Income	$ -9.06M	$ -15.62M	$ -15.75M	$ -8.96M	$ -7.39M	$ -4.25M
Net Non Operating Interest Income Expense	-	-	$ 3.40K	-	-	-
Other Income Expense	$ -492.86K	$ -171.00K	$ -1.46M	$ 18.53K	$ -141.75K	$ -377.00
Pretax Income	$ -19.40M	$ -15.45M	$ -14.29M	$ -8.94M	$ -7.53M	$ -4.26M
Tax Provision	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -9.01M	$ -15.45M	$ -14.29M	$ -8.94M	$ -7.53M	$ -4.26M
Basic EPS	$ -1.67	$ -1.83	$ -2.24	$ -5.60	$ -7.00	$ -5.00
Diluted EPS	$ -1.08	$ -1.83	$ -2.24	$ -5.60	$ -7.00	$ -5.00
Basic Average Shares	$ 49.68M	$ 8.44M	$ 6.37M	$ 1.60M	$ 1.08M	$ 817.57K
Diluted Average Shares	$ 41.24M	$ 8.44M	$ 6.37M	$ 1.60M	$ 1.08M	$ 817.57K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 9.59M	$ 16.81M	$ 15.75M	$ 9.86M	$ 8.40M	$ 5.27M
Net Income From Continuing And Discontinued Operation	$ -19.24M	$ -15.45M	$ -14.29M	$ -8.94M	$ -7.53M	$ -4.26M
Normalized Income	$ -7.43M	-	-	$ -8.96M	$ -7.39M	$ -4.25M
Interest Expense	-	-	-	-	-	-
EBIT	$ -19.40M	$ -15.45M	$ -14.29M	$ -8.96M	$ -7.39M	$ -4.25M
EBITDA	$ -14.88M	$ -15.43M	$ -14.28M	$ -8.95M	$ -7.39M	$ -4.24M

Currency in USD

Cyclo Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing